Verastem (VSTM) Cash & Equivalents (2011 - 2026)

Verastem has reported Cash & Equivalents for 16 years, with the latest figure at $165.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 40.81% year-over-year to $165.6 million; the trailing twelve-month figure through Mar 2026 stood at $165.6 million (up 40.81% YoY), and the FY2025 full-year result was $205.0 million, up 130.8% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $165.6 million, down from $205.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $205.0 million in Q4 2025, with the low at $46.7 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $110.5 million, with a median of $95.0 million recorded in 2023.
• Year-over-year, Cash & Equivalents soared 221.49% in 2022 and slumped 54.46% in 2024.
• Tracing VSTM's Cash & Equivalents over 5 years: stood at $79.1 million in 2022, then slipped by 1.48% to $77.9 million in 2023, then grew by 14.0% to $88.8 million in 2024, then jumped by 130.8% to $205.0 million in 2025, then decreased by 19.24% to $165.6 million in 2026.
• The last three Cash & Equivalents figures came in at $165.6 million (Q1 2026), $205.0 million (Q4 2025), and $137.7 million (Q3 2025), per Business Quant data.

Peer Comparison